FusionBeauty to market lux fragrances
This article was originally published in The Rose Sheet
Executive Summary
Fusion Brands' beauty unit announces formation of a luxury fragrance division, bringing company "one step closer to realizing our goal in becoming a full service global beauty entity," CEO Caroline Pieper-Vogt says. Fragrance veteran Dana Kline will oversee the new business, responsible for "garnering new business partnerships, identifying expansion opportunities and pioneering product development." Before joining Fusion, Kline was president of ICON Beauty, a sales and distribution company she launched in 2008, handling sales and marketing for Beyonce Heat, Nautica, Nautica Oceans, Kate Moss and Beckham scents, plus the exclusive launch of bebe fragrances in the U.S., according to April 13 release. She also has served in executive and managerial sales capacities at Gary Farn Ltd., heading up distribution for prestige fragrance houses including Ferragamo, Annick Goutal and Lolita Lempicka, and at Puig Prestige and LVMH. Fusion welcomes her "unique combination of passion for the fragrance category, her extensive management experience and her unparalleled skill at brand development." FusionBeauty also offers LipFusion, StimuLashFusion, LiftFusion and GlowFusion
You may also be interested in...
In Brief
FDA Raises Eyebrow At RapidLash Claims
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip